Telum Therapeutics
Summary active Updated Jul 1, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Telum Therapeutics is a Spanish biotech company developing protein-based antimicrobial therapeutics for multidrug-resistant infections. Founded in 2019 and based in Pamplona (Navarra), Spain, Telum uses its proprietary APEX® platform — combining metagenomic datasets, synthetic biology, and generative AI — to design biologically derived antimicrobial candidates 12. The lead program targets hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Acinetobacter baumannii, a multidrug-resistant Gram-negative pathogen 123.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-01 | Series A | €18M | AMR Action Fund | Inveready, Invivo Partners, CDTI/SICC Innvierte, Clave Capital, Sodena 1235 |
| 2020 | Seed | €4.1M | Invivo Ventures | Clave Capital, CDTI-Innvierte 4 |
What Investors Say
“Acinetobacter baumannii is one of the most formidable bacterial threats in modern medicine.” — Dr. Henry Skinner, CEO, AMR Action Fund, quoted in the Series A announcement, 2026 2
What Founders Say
“This financing provides a clear path to complete Phase 1 development of our lead program targeting Acinetobacter baumannii HABP/VABP.” — Dr. Subhendu Basu, CEO, Telum Therapeutics, quoted in the Series A announcement, 2026 2
“This financing marks an important milestone for the Company and reflects the strength of our scientific platform.” — Dr. Roberto Díez, Founder & COO, Telum Therapeutics, quoted in the Series A announcement, 2026 2
Sources
-
EU-Startups, “Telum Therapeutics raised €18 million to advance treatments for hospital-acquired infections,” July 1, 2026. Accessed July 2026. https://www.eu-startups.com/2026/07/telum-therapeutics-raised-e18-million-to-advance-treatments-for-hospital-acquired-infections/↩↩↩
-
International Biopharmaceutical Industry, “Telum Therapeutics Secures €18 Million Series A Financing to Advance Lead Antimicrobial Programme into Clinical Development,” 2026. Accessed July 2026. https://international-biopharma.com/telum-therapeutics-secures-e18-million-series-a-financing-to-advance-lead-antimicrobial-programme-into-clinical-development/↩↩↩↩↩↩
-
BioTech NewsWire, “Telum Therapeutics Secures €18 Million Series A Financing to Advance Lead Antimicrobial Program into Clinical Development,” June 30, 2026. Accessed July 2026. https://www.biotechnewswire.ai/202606302805/telum-therapeutics-secures-18-million-series-a-financing-to-advance-lead-antimicrobial-program-into-clinical-development.html↩↩
-
Telum Therapeutics, “Telum Therapeutics raises €4.1 million in its first round of financing,” accessed July 2026. https://telumtherapeutics.com/telum-therapeutics-raises-e-4-1-million-in-its-first-round-of-financing-to-advance-the-development-of-new-synthetic-biology-based-therapies-for-the-treatment-of-infectious-diseases-caused-by-multi-res/↩
-
BeBeez International, “Telum Therapeutics raised €18 million to advance treatments for hospital-acquired infections,” July 1, 2026. Accessed July 2026. https://bebeez.eu/2026/07/01/telum-therapeutics-raised-e18-million-to-advance-treatments-for-hospital-acquired-infections/↩